Deep learning approaches for predicting drug responses from multi-omics features

Cancer is a pathological process resulting from the accumulation of mutations. Depending on cellular aberrations and inducement of abnormal growth, cancer is staged in the clinic for treatment selection. Treatment of cancer needs to be customised due to the complexity of each cancer. The advancemen...

全面介紹

Saved in:
書目詳細資料
主要作者: Sneha, Palaniappan
其他作者: Jagath C Rajapakse
格式: Final Year Project
語言:English
出版: Nanyang Technological University 2021
主題:
在線閱讀:https://hdl.handle.net/10356/148237
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!
機構: Nanyang Technological University
語言: English
實物特徵
總結:Cancer is a pathological process resulting from the accumulation of mutations. Depending on cellular aberrations and inducement of abnormal growth, cancer is staged in the clinic for treatment selection. Treatment of cancer needs to be customised due to the complexity of each cancer. The advancement of technology has allowed the collection of biological data types at a detailed level, and the integration of omics data helps to achieve a comprehensive understanding of the underlying biological factors. The integration gives a holistic molecular perspective of the multi-omics approach to optimise cancer treatment. We proposed DNN models to predict anti-cancer drug responses using the multi-omics data obtained from the Cancer Cell Line Encyclopedia (CCLE) and Genomics of Drug Sensitivity in Cancer (GDSC). Due to the high dimensionality nature of multi-omics data and their inherent data variations, effective multi-omics data integration is challenging. These form the motivation for this project to explore dimensionality reduction techniques and deep neural networks. Dimensionality reduction techniques were adopted to tackle the high dimensionality nature of multi-omics data. A combined deep neural network model with an attention mechanism was developed to integrate the omics data to predict drug responses. This will aid to determine the most effective drug combination for personalised cancer treatment.